Urological Oncology
- 作者Stephen A. Boorjian; Fernando J. Bianco Jr; Peter T. Scardino; James A. Eastham
- 卷第96卷
- 期第6期
- 印刷ISSN1464-4096
- 电子ISSN1464-410X
- 文件大小118.48KB
- 发表时间2005
- DOI10.1111/j.1464-410x.2005.05763.x
- 页码773-776
Clinical Benefits and Considerations of Bisphosphonate Treatment in Metastatic Bone DiseaseFred Saad; Allan Lipton · 2007
Pathologic fractures correlate with reduced survival in patients with malignant bone diseaseFred Saad; Allan Lipton; Richard Cook; Yin-Miao Chen; Matthew Smith; Robert Coleman · 2007
SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancerFred Saad; Allan Lipton · 2010
Bone-marker levels in patients with prostate cancer: potential correlations with outcomesSaad, Fred; Lipton, Allan · Current Opinion in Supportive and Palliative Care · 2010
Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate CancerMatthew R. Smith; Richard J. Cook; Robert Coleman; Janet Brown; Allan Lipton; Pierre Major; Yong Jiang Hei; Fred Saad · 2007
Consensus on the utility of bone markers in the malignant bone disease settingRobert Coleman; Luis Costa; Fred Saad; Richard Cook; Peyman Hadji; Evangelos Terpos; Patrick Garnero; Janet Brown; Jean-Jacques Body; Matthew Smith; Ker-Ai Lee; Pierre Major; Meletios Dimopoulos; Allan Lipton · 2011
ZOLEDRONIC ACID IS EFFECTIVE IN PREVENTING AND DELAYING SKELETAL EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO GENITOURINARY CANCERSFRED SAAD; ALLAN LIPTON · 2006